Ann: Trading Halt, page-19

Mid-Way Point Reached in Landmark Alzheimer’s Trial - XanADu
• Major milestone achieved with a total of 87 patients enrolled into XanADu - representing half of the total patients required to complete the trial
• Trial progressing on schedule and expected to enrol the final patient in Q4 2018 with top-line results in Q2 2019
• Interim analysis of XanADu to commence in Q2 2018 once the 50th evaluable patient completes the trial
Sydney, 21 March 2018: Actinogen Medical (ASX: ACW) is pleased to announce it has reached the mid-way point in patient enrolment for its landmark Phase II clinical trial (XanADu) of Xanamem in the treatment of Alzheimer’s disease.
A total of 87 patients have been enrolled into XanADu, representing half of the total 174 patients planned for the study. The trial continues to enrol on target, with the final patient expected in the fourth quarter of this calendar year, and the top-line results by April/May 2019. Importantly, XanADu is fully funded through to the end of the trial...